The DOI matches its Crossref record.
Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies
Open accessAbstract
Summary: Background: Enterocyte damage is the hallmark of coeliac disease (CD) resulting in malabsorption. Little is known about the recovery of enterocyte damage and its clinical consequences. Serum intestinal fatty acid binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. Aims: To evaluate the severity of enterocyte damage in adult‐onset CD and its course upon a gluten‐free diet (GFD). Furthermore, the correlation among enterocyte damage, CD autoantibodies and histological abnormalities during the course of disease is studied. Methods: Serum I‐FABP levels were determined in 96 biopsy‐proven adult CD patients and in 69 patients repeatedly upon a GFD. A total of 141 individuals with normal antitissue transglutaminase antibody (IgA‐tTG) levels served as controls. I‐FABP levels were related to the degree of villous atrophy (Marsh grade) and IgA‐tTG. Results: I‐FABP levels were elevated in untreated CD (median 691 pg/mL) compared with controls (median 178 pg/mL, P < 0.001) and correlated with Marsh grade (r = 0.265, P < 0.05) and IgA‐tTG (r = 0.403, P < 0.01). Upon a GFD serum levels decreased significantly, however, not within the range observed in controls, despite the common observed normalisation of IgA‐tTG levels and Marsh grade. CD patients with elevated I‐FABP levels nonresponding to GFD showed persistent histological abnormalities. Conclusions: Enterocyte damage assessed by serum I‐FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA‐tTG levels in the majority of cases. Elevated I‐FABP levels nonresponding to gluten‐free diet are indicative of histological abnormalities and warrant further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
Self-citationHomeostasis of the gut barrier and potential biomarkers
Wells, J. M., Brummer, R. J., Derrien, M., MacDonald, T. T., Troost, F., Cani, P. D., Theodorou, V., Dekker, J., Méheust, A., de Vos, W. M., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00048.2015 · Cited by 620
Celiac disease and non-celiac gluten sensitivity
Lebwohl, B., Ludvigsson, J. F., & Green, P. H. R. (2015) · BMJ · doi:10.1136/bmj.h4347 · Cited by 308
Silvester, J. A., Kurada, S., Szwajcer, A., Kelly, C. P., Leffler, D. A., & Duerksen, D. R. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.05.015 · Cited by 235
Ouyang, J., Lin, J., Isnard, S., Fombuena, B., Peng, X., Marette, A., Routy, B., Messaoudene, M., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00645 · Cited by 124
Metadata
- Authors
- Adriaanse, M. P. M., Tack, G. J., Passos, V. L., Damoiseaux, J. G. M. C., Schreurs, M. W. J., van Wijck, K., Riedl, R. G., Masclee, A. A. M., Buurman, W. A., Mulder, C. J. J., & Vreugdenhil, A. C. E.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-01-07
- Volume
- 37
- Issue
- 4
- Pages
- 482-490
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1994195708
- Cited by
- 199
- References
- 0
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. https://app.cochat.ai/papers/10.1111/apt.12194
- The paper
- Adriaanse, M. P. M., Tack, G. J., Passos, V. L., Damoiseaux, J. G. M. C., Schreurs, M. W. J., van Wijck, K., Riedl, R. G., Masclee, A. A. M., Buurman, W. A., Mulder, C. J. J., & Vreugdenhil, A. C. E. (2013). Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.12194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.